CIK 0001662579 · Non-accelerated filer<br>Smaller reporting company
C4 Therapeutics, Inc.
Sign in to watch- Ticker
- CCCC
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 475617627
- Phone
- (617) 231-0700
- Business address
- 490 ARSENAL WAY, SUITE 120, WATERTOWN, MA, 02472
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-02-11 | Wahlberg Laura Jean VP of Finance Corp Controller | Grant or award · Stock Option (Right to Buy) | +23,100 | 23,100 | ||
| 2021-02-11 | Fisher Stewart Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +94,950 | 94,950 | ||
| 2021-02-11 | Siegel Jolie Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +84,850 | 84,850 | ||
| 2021-02-11 | Crystal Adam Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +87,850 | 87,850 | ||
| 2021-02-03 | Fisher Stewart Chief Scientific Officer | Option exercise | +2,371 | $2.11 | $5K | 102,187 |
| 2021-02-03 | Fisher Stewart Chief Scientific Officer | Option exercise | +5,929 | $3.71 | $22K | 108,116 |
| 2021-02-03 | Fisher Stewart Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) | −2,371 | 2,371 | ||
| 2021-02-03 | Fisher Stewart Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) | −5,929 | 55,514 | ||
| 2021-01-22 | Anderson Kenneth Carl Director | Option exercise | +538 | $2.11 | $1K | 80,914 |
| 2021-01-22 | Anderson Kenneth Carl Director | Option exercise | +121 | $2.11 | $255 | 81,035 |
| 2021-01-22 | Anderson Kenneth Carl Director | Option exercise | +889 | $4.98 | $4K | 81,924 |
| 2021-01-22 | Anderson Kenneth Carl Director | Option exercise · Stock Option (Right to Buy) | −538 | 3,207 | ||
| 2021-01-22 | Anderson Kenneth Carl Director | Option exercise · Stock Option (Right to Buy) | −121 | 0 | ||
| 2021-01-22 | Anderson Kenneth Carl Director | Option exercise · Stock Option (Right to Buy) | −889 | 4,446 | ||
| 2020-12-11 | Fisher Stewart Chief Scientific Officer | Option exercise | +4,743 | $2.11 | $10K | 90,115 |
| 2020-12-11 | Fisher Stewart Chief Scientific Officer | Option exercise | +9,701 | $3.71 | $36K | 99,816 |
| 2020-12-11 | Fisher Stewart Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) | −4,743 | 4,742 | ||
| 2020-12-11 | Fisher Stewart Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) | −9,701 | 61,443 | ||
| 2020-10-06 | MCKEE WILLIAM Chief Financial Officer | Purchase | +5,263 | $19.00 | $100K | 5,263 |
| 2020-10-06 | COHEN MARC A Director | Conversion | +237,149 | 370,024 |
Page 24 of 27 · 525 trades